Cargando…
CD38 Antibodies in Multiple Myeloma: Mechanisms of Action and Modes of Resistance
MM cells express high levels of CD38, while CD38 is expressed at relatively low levels on normal lymphoid and myeloid cells, and in some non-hematopoietic tissues. This expression profile, together with the role of CD38 in adhesion and as ectoenzyme, resulted in the development of CD38 antibodies fo...
Autores principales: | van de Donk, Niels W.C.J., Usmani, Saad Z. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6158369/ https://www.ncbi.nlm.nih.gov/pubmed/30294326 http://dx.doi.org/10.3389/fimmu.2018.02134 |
Ejemplares similares
-
Comparison of CD38 antibodies in vitro and ex vivo mechanisms of action in multiple myeloma
por: Kinder, Michelle, et al.
Publicado: (2021) -
Resistance Mechanisms towards CD38−Directed Antibody Therapy in Multiple Myeloma
por: Franssen, Laurens E., et al.
Publicado: (2020) -
Trogocytosis represents a novel mechanism of action of daratumumab in multiple myeloma
por: Krejcik, Jakub, et al.
Publicado: (2018) -
CD38-Directed Therapies for Management of Multiple Myeloma
por: Hashmi, Hamza, et al.
Publicado: (2021) -
CD38-targeted therapy with daratumumab reduces autoantibody levels in multiple myeloma patients
por: Frerichs, Kristine A., et al.
Publicado: (2019)